About Indoleamine 2,3-dioxygenase 1
Indoleamine 2,3-dioxygenase 1 (IDO1) is a protein
from Homo sapiens identified by UniProt accession
P14902, 403 residues long.
MolForge cross-references it against 0 known binders and
924 disease associations.
Target properties
| Protein name | Indoleamine 2,3-dioxygenase 1 |
| UniProt accession | P14902 |
| Gene | IDO1 |
| Organism | Homo sapiens |
| Length | 403 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (13)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (924)
Diseases linked to this target (Open Targets).
- melanoma · score 0.36
- head and neck malignant neoplasia · score 0.36
- lung cancer · score 0.34
- urogenital neoplasm · score 0.32
- neoplasm · score 0.31
- non-small cell lung carcinoma · score 0.30
- renal cell carcinoma · score 0.28
- skin cancer · score 0.26
- inflammatory bowel disease · score 0.16
- cancer · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P14902-F1 | alphafold | PREDICTED | 93.08 | — |
Amino-acid sequence (403 residues)
MAHAMENSWT ISKEYHIDEE VGFALPNPQE NLPDFYNDWM FIAKHLPDLI ESGQLRERVE KLNMLSIDHL TDHKSQRLAR LVLGCITMAY VWGKGHGDVR KVLPRNIAVP YCQLSKKLEL PPILVYADCV LANWKKKDPN KPLTYENMDV LFSFRDGDCS KGFFLVSLLV EIAAASAIKV IPTVFKAMQM QERDTLLKAL LEIASCLEKA LQVFHQIHDH VNPKAFFSVL RIYLSGWKGN PQLSDGLVYE GFWEDPKEFA GGSAGQSSVF QCFDVLLGIQ QTAGGGHAAQ FLQDMRRYMP PAHRNFLCSL ESNPSVREFV LSKGDAGLRE AYDACVKALV SLRSYHLQIV TKYILIPASQ QPKENKTSED PSKLEAKGTG GTDLMNFLKT VRSTTEKSLL KEG
Explore Indoleamine 2,3-dioxygenase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets